From the Department of Biopharmaceutics and Clinical Pharmacy (Mousa, Hammad); and from the Department of General Surgery (Melhem), Faculty of Medicine-University of Jordan, Amman, Jordan.
Saudi Med J. 2021 Jul;42(7):776-783. doi: 10.15537/smj.2021.42.7.20210112.
To evaluate the epidemiology, prognostic factors, and 5-year overall survival (OS) of females with breast cancer (BC) diagnosed between 2011 and 2014 in Jordan.
A retrospective medical review of females who were diagnosed with BC between 2011 and 2014 at the 2 leading public health providers in Jordan was performed. The endpoint of the study was 2018. Data were extracted from the medical files between 2011 and 2018, including demographic clinical data on the patient level. Survival by age, laterality, grade, stage, and treatments modes were calculated by the Kaplan Meier method.
A total of 877 women were included with median age of 51 years and follow-up duration of 2.4 years. Majority of the patients had ductal carcinoma and estrogen receptor (ER) positive type. The 5-year OS for patients with stage I, II, III, and IV, 94%, 86%, and 46% (<0.001), respectively. The tumor stage and nodal status were the main prognostic variables affecting the overall survival.
The incidence in Jordan is increasing, yet survival rates are improving with increased diagnosis during early stages. Therefore, strategies for implementing universal screening programs are advocated to improve clinical outcomes and to reduce the disease burden.
评估 2011 年至 2014 年间在约旦诊断出的女性乳腺癌（BC）的流行病学、预后因素和 5 年总生存率（OS）。
对 2011 年至 2014 年间在约旦 2 家主要公共卫生机构诊断出的女性 BC 患者进行回顾性医学审查。研究终点为 2018 年。数据从 2011 年至 2018 年的病历中提取，包括患者层面的人口统计学和临床数据。通过 Kaplan-Meier 方法计算按年龄、侧别、分级、分期和治疗模式的生存率。
共纳入 877 名女性，中位年龄为 51 岁，随访时间为 2.4 年。大多数患者为导管癌，雌激素受体（ER）阳性型。I 期、II 期、III 期和 IV 期患者的 5 年 OS 分别为 94%、86%和 46%（<0.001）。肿瘤分期和淋巴结状态是影响总体生存的主要预后变量。
约旦的发病率在增加，但由于早期诊断率的提高，生存率在提高。因此，提倡实施普遍筛查计划的策略，以改善临床结果并减轻疾病负担。
